• 1. Lanthanide–EDTA complexes covalently bonded on Fe3O4@SiO2 magnetic nanoparticles promote the green, stereoselective synthesis of N-acylhydrazones
  Jo?o Batista M. de Resende Filho,Nathália Kellyne S. M. Falc?o,Gilvan P. Pires,Luiz Fernando S. de Vasconcelos,Sávio M. Pinheiro,José Maurício dos Santos Filho,Marília Imaculada Fraz?o Barbosa,Ant?nio Carlos Doriguetto,Ercules E. S. Teotonio,Juliana A. Vale New J. Chem. 2019 43 14257

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives

Benzoic acid, 2-cyclohexylidenehydrazide (CAS No. 24214-79-7): A Comprehensive Overview in Modern Chemical Research

Benzoic acid, 2-cyclohexylidenehydrazide, identified by its unique Chemical Abstracts Service (CAS) number 24214-79-7, represents a significant compound in the realm of organic chemistry and pharmaceutical research. This heterocyclic derivative has garnered attention due to its structural versatility and potential applications in medicinal chemistry. The compound’s molecular framework, featuring a benzoyl group linked to a cyclohexylidenehydrazine moiety, positions it as a valuable intermediate in the synthesis of bioactive molecules.

The chemical structure of benzoic acid, 2-cyclohexylidenehydrazide (CAS No. 24214-79-7) is characterized by its aromatic ring system and the presence of both carbonyl and hydrazine functionalities. This dual reactivity allows for diverse chemical transformations, making it a promising candidate for the development of novel pharmaceutical agents. The cyclohexylidene moiety introduces steric hindrance, which can influence the compound’s pharmacokinetic properties, including solubility and metabolic stability.

In recent years, the investigation of benzoic acid derivatives has been extensively explored for their therapeutic potential. Among these derivatives, compounds like benzoic acid, 2-cyclohexylidenehydrazide (CAS No. 24214-79-7) have been studied for their ability to modulate biological pathways associated with inflammation and oxidative stress. Preliminary studies suggest that this compound may exhibit inhibitory effects on certain enzymes involved in these pathways, making it a candidate for further exploration in drug discovery.

The synthesis of benzoic acid, 2-cyclohexylidenehydrazide (CAS No. 24214-79-7) typically involves multi-step organic reactions, starting from commercially available precursors such as benzoyl chloride and cyclohexanone hydrazine. The reaction sequence often includes condensation reactions followed by cyclization steps to form the desired heterocyclic structure. Advances in synthetic methodologies have enabled more efficient and scalable production processes, facilitating its use in both academic research and industrial applications.

One of the most compelling aspects of benzoic acid, 2-cyclohexylidenehydrazide (CAS No. 24214-79-7) is its potential as a scaffold for drug design. By modifying its core structure or appending functional groups, researchers can generate libraries of derivatives with tailored biological activities. For instance, substituting the cyclohexylidene moiety with other aromatic or heteroaromatic groups could alter the compound’s binding affinity to target proteins or enzymes. Such structural modifications are crucial in optimizing drug candidates for efficacy and selectivity.

Recent computational studies have also highlighted the importance of molecular modeling in understanding the interactions between benzoic acid, 2-cyclohexylidenehydrazide (CAS No. 24214-79-7) and biological targets. These studies utilize advanced algorithms to predict binding affinities and identify key interaction sites on proteins relevant to therapeutic intervention. By integrating experimental data with computational insights, researchers can accelerate the discovery process and prioritize promising candidates for further validation.

The pharmacological profile of benzoic acid derivatives, including benzoic acid, 2-cyclohexylidenehydrazide (CAS No. 24214-79-7), continues to be an area of active investigation. Researchers are particularly interested in exploring its potential as an anti-inflammatory agent due to its ability to inhibit key mediators of inflammation such as COX enzymes and lipoxygenases. Additionally, its antioxidant properties make it a candidate for applications in neuroprotective therapies aimed at mitigating oxidative damage associated with neurological disorders.

In conclusion, benzoic acid, 2-cyclohexylidenehydrazide (CAS No. 24214-79-7) represents a fascinating compound with significant potential in pharmaceutical research. Its unique structural features and versatile reactivity make it a valuable tool for developing novel therapeutic agents targeting various diseases. As research progresses, further exploration of this compound’s biological activities and synthetic modifications will undoubtedly contribute to advancements in drug discovery and development.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)